Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
A Clinical Gene Therapy Study with Hematopoietic Stem Cells for the Treatment, with Single Dose of Temferon, of Patients Suffering from Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genenta Science
- Target Recruit Count
- 12
- Registration Number
- NCT06716853
- Locations
- 🇮🇹
Ospedale San Raffaele, Milan, Italy
Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 80
- Registration Number
- NCT06548867
- Locations
- 🇮🇹
AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy
A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 40
- Registration Number
- NCT06535737
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT06482086
- Locations
- 🇨🇳
West China hospital, Chengdu, Sichuan, China
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 264
- Registration Number
- NCT06475989
- Locations
- 🇺🇸
Idaho Urologic Institute-Meridian, Meridian, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 18
- Registration Number
- NCT06377722
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario de Valdecilla, Santander, Cantabria, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
CARE1 Pragmatic Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1250
- Registration Number
- NCT06364631
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 90
- Registration Number
- NCT06341712
- Locations
- 🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Belgium
🇨🇦Princess Margaret cancer center, Toronto, Canada
🇺🇸University of Southern California (USC) - Norris Cancer Hospital, Los Angeles, California, United States
caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 33
- Registration Number
- NCT06171854
- Locations
- 🇮🇹
A.O.U dell'Università degli Studi della Campania "Luigi Vanvitelli", Napoli, Italy
Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 30
- Registration Number
- NCT06156410
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.